HomeCompareFWDG vs ABBV

FWDG vs ABBV: Dividend Comparison 2026

FWDG yields 6666666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FWDG wins by $8.25873857526507e+44M in total portfolio value
10 years
FWDG
FWDG
● Live price
6666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.25873857526507e+44M
Annual income
$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00
Full FWDG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FWDG vs ABBV

📍 FWDG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFWDGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FWDG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FWDG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FWDG
Annual income on $10K today (after 15% tax)
$566,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FWDG beats the other by $701,972,065,618,006,100,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FWDG + ABBV for your $10,000?

FWDG: 50%ABBV: 50%
100% ABBV50/50100% FWDG
Portfolio after 10yr
$4.129369287632535e+44M
Annual income
$412,924,744,481,180,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FWDG
No analyst data
Altman Z
-0.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FWDG buys
0
ABBV buys
0
No recent congressional trades found for FWDG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFWDGABBV
Forward yield6666666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.25873857526507e+44M$102.3K
Annual income after 10y$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.258722632802889e+44M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FWDG vs ABBV ($10,000, DRIP)

YearFWDG PortfolioFWDG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$666,677,367$666,666,666.67$11,550$430.00+$666.67MFWDG
2$41,538,243,978,220$41,537,530,633,437.17$13,472$627.96+$41538243.96MFWDG
3$2,418,785,178,923,619,000$2,418,740,733,002,562,000.00$15,906$926.08+$2418785178923.60MFWDG
4$131,632,535,180,835,430,000,000$131,629,947,080,693,970,000,000.00$19,071$1,382.55+$131632535180835424.00MFWDG
5$6,694,929,569,421,761,000,000,000,000$6,694,788,722,609,116,000,000,000,000.00$23,302$2,095.81+$6.69492956942176e+21MFWDG
6$318,233,313,948,923,370,000,000,000,000,000$318,226,150,374,284,100,000,000,000,000,000.00$29,150$3,237.93+$3.1823331394892335e+26MFWDG
7$14,137,160,116,927,522,000,000,000,000,000,000,000$14,136,819,607,281,600,000,000,000,000,000,000,000.00$37,536$5,121.41+$1.4137160116927522e+31MFWDG
8$586,942,647,681,175,100,000,000,000,000,000,000,000,000$586,927,520,919,850,000,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$5.8694264768117504e+35MFWDG
9$22,774,359,015,829,920,000,000,000,000,000,000,000,000,000,000$22,773,730,987,196,898,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.277435901582992e+40MFWDG
10$825,873,857,526,507,000,000,000,000,000,000,000,000,000,000,000,000$825,849,488,962,360,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.25873857526507e+44MFWDG

FWDG vs ABBV: Complete Analysis 2026

FWDGStock

FutureWorld Corp., together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of hemp/cannabis products, services, and technologies worldwide. The company provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation, and consultation for the industrial hemp and legal medicinal marijuana. It offers personal and professional tetrahydrocannabinoil and Cannabidiol test kits; pharmaceutical grade CBD oil solutions; URVape vaporizer pens, which are oil vaporizers for the e-cigarette, cannabis, and herbal vaping industry; CaNNaLyTiX, a dashboard controller system that allows various computer systems to be integrated throughout a cultivator's infrastructures; CaNNaTRAK, the barcode and RFID tracking systems for keeping seed to sale tracking of hemp/cannabis; and SPIDer (secure perimeter intrusion detection network), a system to meet the needs of theft and malicious attacks. The company also provides SmartSense, which offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry; SmartNergy that offers tools to analyze various aspects of a cultivator's energy usage; and CaNNaBoX machine, which operates with the swipe of a card to verify identity, age, and prescription information of a medical marijuana patient before releasing measured packages of marijuana. Its target customers include consumers via Internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, affiliate sales, and master distributors. The company was formerly known as FutureWorld Energy, Inc. and changed its name to FutureWorld Corp. in June 2014. FutureWorld Corp. was founded in 2002 and is based in Saint Petersburg, Florida.

Full FWDG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FWDG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FWDG vs SCHDFWDG vs JEPIFWDG vs OFWDG vs KOFWDG vs MAINFWDG vs JNJFWDG vs MRKFWDG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.